Answers are grounded in this paper and cite their sources.
Purpose To investigate the clinical potential of O -(2-[ 18 F]fluoroethyl)-L-tyrosine ([ 18 F]FET) PET imaging in the management of circumscribed astrocytic gliomas (CAG), a rare glioma subtype with limited imaging data. Methods We retrospectively identified adult CAG patients who underwent [ 18 F]FET PET imaging (i) before diagnosis, (ii) at suspected relapse, or (iii) for response assessment at three institutions. Maximum and mean tumor-to-brain ratios (TBR max , TBR mean ) and metabolic tumor volumes were assessed according to the PET RANO 1.0 criteria. Diagnostic performance in differentiating treatment-related changes from tumor relapse was evaluated using ROC analysis and Fisher’s exact test. Results We evaluated 79 [ 18 F]FET PET scans of 42 patients, including nine (21%) with actionable molecular targets. Measurable [ 18 F]FET uptake was observed in 65% of WHO grade 1 and 100% of WHO grade 2 and 3 CAG. TBR values were significantly higher in WHO grade 2 and 3 CAG than in pilocytic astrocytomas ( P < 0.01), but showed no difference based on molecular target status ( P > 0.05). In 5 of 11 patients (45%), treatment response assessment by PET RANO 1.0 differed from MRI. Treatment-related changes were confirmed in 12 patients (43%). In CAG WHO grades 2 or 3, the accuracy of [ 18 F]FET PET to identify treatment-related changes was 82% using single PET scans and 100% using serial PET imaging ( P < 0.05). Conclusions [ 18 F]FET PET can contribute to clinical management of patients with CAG by detecting measurable disease, differentiating treatment-related changes from tumor progression, and showing potential in treatment response assessment through longitudinal imaging.
No takes yet. Share an insight, caveat, or question.
Werner et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: